Seeking Alpha

Seeking Alpha Portfolio App for iPad

This Market Current was sent to 2,377 people who get email alerts on EXEL.

Get email alerts on EXEL »

Market Currents

The FDA has approved Exelixis' (EXEL) cabozantinib thyroid cancer drug. Shares are halted....

Thursday, November 29, 2012, 4:18 PM ET
The FDA has approved Exelixis' (EXEL) cabozantinib thyroid cancer drug. Shares are halted. (previous)

This Market Current was sent to 2,377 people who get email alerts on EXEL.

Get email alerts on EXEL »

Share this Market Current

Short URL:

Other date

DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles

Thermo Fisher A Decent Long-Term Opportunity
11:35 AM • Fundamental Analyst
A Game-Changing Cancer Screen For Exact Sciences
10:57 AM • Biotech Vet
Long-Term Biotech: 3 Names To Discover Now
9:42 AM • G. Putnam Kling
Will Influenza A H7N9 Generate Opportunities For Pharma?
9:10 AM • Jean-Christophe Larsimont
Neuralstem: Update On Phase I Trial Of Neural Stem Cells In ALS Is Encouraging
8:18 AM • Smith On Stocks
The Facebook Effect On Arena's Belviq Sales And Why It Will Ultimately Dwarf Anything Eisai Does
6:56 AM • Jacob Smith
Bristol Myers Squibb And The New Wave Of Cancer Drugs
4:34 PM • Peter Geschek
Johnson & Johnson's Short-Term Pipeline
3:15 PM • Jean-Christophe Larsimont
Vascepa Data Should Make Amarin Longs Worried
12:55 PM • Quoth the Raven
A Focus On Stem-Cell Therapy And Regenerative Medicine For 2013
11:38 AM • A John Hodge
Catalyst Pharmaceutical's CPP-115 May Be Big Pipeline In Just One Little Pill
11:30 AM • Michael_Anderson
3 Small Cap Cancer Stocks With Upcoming Catalysts
11:15 AM • Equity Options Guru
PSivida Corporation And GTx: 2 Of The Most Undervalued Biotechs For 2013
10:32 AM • Bob's Stocks
AstraZeneca: A Dividend Payer With An Attractive Growth Prospect
9:59 AM • Fund Gurus
Value Investors Take Note: Fire Sale On This Heart Failure Asset
9:48 AM • PropThink

More Latest Articles »